1. A Novel Antagonist Peptide Reveals a Physiological Role of Insulin-Like Peptide 5 in Control of Colorectal Function
- Author
-
John B. Furness, Praveen Praveen, Mohammed Akhter Hossain, Shuai Nie, Qinghao Ou, Ruslan V Pustovit, Jamie Jm Liew, Xiaozhou Zhang, Martina Kocan, Lalita Oparija-Rogenmozere, Mengjie Liu, Ada Koo, and Ross A. D. Bathgate
- Subjects
Pharmacology ,Relaxin ,chemistry.chemical_classification ,Agonist ,medicine.drug_class ,Antagonist ,Motility ,Peptide ,Ligand (biochemistry) ,In vitro ,chemistry ,medicine ,Pharmacology (medical) ,Relaxin/insulin-like family peptide receptor 2 - Abstract
[Image: see text] Insulin-like peptide 5 (INSL5), the natural ligand for the relaxin family peptide receptor 4 (RXFP4), is a gut hormone that is exclusively produced by colonic L-cells. We have recently developed an analogue of INSL5, INSL5-A13, that acts as an RXFP4 agonist in vitro and stimulates colorectal propulsion in wild-type mice but not in RXFP4-knockout mice. These results suggest that INSL5 may have a physiological role in the control of colorectal motility. To investigate this possibility, in this study we designed and developed a novel INSL5 analogue, INSL5-A13NR. This compound is a potent antagonist, without significant agonist activity, in two in vitro assays. We report here for the first time that this novel antagonist peptide blocks agonist-induced increase in colon motility in mice that express RXFP4. Our data also show that colorectal propulsion induced by intracolonic administration of bacterial products (short-chain fatty acids, SCFAs) is antagonized by INSL5-A13NR. Therefore, INSL5-A13NR is an important research tool and potential drug lead for the treatment of colon motility disorders, such as bacterial diarrheas.
- Published
- 2021
- Full Text
- View/download PDF